Drugs / ST-1898
ST-1898
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06359860 | Nov 2023 → Dec 2026 expected | melanoma | Beijing Scitech-Mq Pharmaceuticals Limited | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06127238 | Feb 2023 → Dec 2025 overdue | renal cell carcinoma | Beijing Scitech-Mq Pharmaceuticals Limited | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06359847 | Nov 2023 → Dec 2027 expected | differentiated thyroid carcinoma | Beijing Scitech-Mq Pharmaceuticals Limited | Recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ST-1898 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06359860 ↗ |
| Action | Inhibit | “ST-1898 is a receptor tyrosine kinase (RTK) inhibitor” NCT06127238 ↗ |
| Route | Oral | “participants will be administered orally at 100mg,140mg,160mg,180mg, 220mg,QD during the study” NCT06127238 ↗ |
| Target | AXL | “ST-1898 is a receptor tyrosine kinase (RTK) inhibitor for multi-targets, especially for VEGFR2, c-MET, AXL，PDGFRA，RET，KIT etc.” NCT06127238 ↗ |
| Target | KIT | “ST-1898 is a receptor tyrosine kinase (RTK) inhibitor for multi-targets, especially for VEGFR2, c-MET, AXL，PDGFRA，RET，KIT etc.” NCT06127238 ↗ |
| Target | PDGFRA | “ST-1898 is a receptor tyrosine kinase (RTK) inhibitor for multi-targets, especially for VEGFR2, c-MET, AXL，PDGFRA，RET，KIT etc.” NCT06127238 ↗ |
| Target | RET | “ST-1898 is a receptor tyrosine kinase (RTK) inhibitor for multi-targets, especially for VEGFR2, c-MET, AXL，PDGFRA，RET，KIT etc.” NCT06127238 ↗ |